Immunoglobulin heavy and light chain genes (IGH/IGK/IGL)

The immunoglobulin heavy and light chain genes (IGH, IGK, and IGL) are the genomic loci responsible for encoding the structural components of antibodies and B-cell receptors (BCRs). These loci are unique for their ability to undergo somatic V(D)J recombination and class-switch recombination, processes essential for generating the diverse repertoire of the adaptive immune system (Janeway et al., 2001). In clinical oncology, these genes are critical as their clonal rearrangements serve as definitive biomarkers for B-cell malignancies, and specific chromosomal translocations involving the IGH locus (e.g., t(14;18) in follicular lymphoma) are primary drivers of oncogenesis (Kuppers, 2005). While the genes themselves are primarily targets for diagnostic sequencing and minimal residual disease monitoring, their protein products—immunoglobulins—are the direct targets of therapeutic agents such as Omalizumab, which neutralizes IgE to treat allergic conditions (Gould & Sutton, 2008). Therapeutic strategies often focus on modulating the expression of these genes or neutralizing the resulting antibodies to manage autoimmune disorders, allergies, and B-cell cancers (StatPearls, 2023). Overall, these genes represent a cornerstone of both diagnostic and therapeutic approaches in immunology and hematology.

Other names

B-cell receptor genesAntibody genesImmunoglobulin lociV(D)J recombination lociIGHIGKIGL

Neutralization of secreted immunoglobulins or depletion of B-cells expressing specific surface immunoglobulins to modulate immune responses.